Response-adapted consolidation with bortezomib after ASCT improves progression-free survival in newly diagnosed multiple myeloma

被引：21

作者：

Einsele, H. ^{[1
]}

Knop, S. ^{[1
]}

Vogel, M. ^{[2
]}

Mueller, J. ^{[3
]}

Kropff, M. ^{[4
]}

Metzner, B. ^{[5
]}

Langer, C. ^{[6
]}

Sayer, H. ^{[7
]}

Jung, W. ^{[8
]}

Duerk, H. A. ^{[9
]}

Salwender, H. ^{[10
]}

Wandt, H. ^{[11
]}

Bassermann, F. ^{[12
]}

Gramatzki, M. ^{[13
]}

Roesler, W. ^{[14
]}

Wolf, H-H ^{[15
]}

Brugger, W. ^{[16
]}

Engelhardt, M. ^{[17
]}

Fischer, T. ^{[18
]}

Liebisch, P. ^{[6
]}

Straka, C. ^{[19
]}

机构：

[1] Julius Maximilians Univ Wurzburg, Med Klin & Poliklin 2, Wurzburg, Germany

[2] Janssen Cilag GmbH, Neuss, Germany

[3] Acromion GmbH, Frechen, Germany

[4] Univ Klinikum Munster, Munster, Germany

[5] Klinikum Oldenburg Klin Onkol & Hamatol, Oldenburg, Germany

[6] Univ Klinikum Ulm, Zentrum Innere Med, Ulm, Germany

[7] Univ Hosp Jena, Jena, Germany

[8] Onkol Univ Med Gottingen, Gottingen, Germany

[9] St Marien Hosp Hamm Knappenstr, Hamm, Germany

[10] Asklepios Klin Altona, Hamburg, Germany

[11] Med Klin 5 Hamatol & Onkol, Nurnberg, Germany

[12] Tech Univ Munich, Med Klin, Munich, Germany

[13] Univ Klinikum Schleswig Holstein, Kiel, Germany

[14] Univ Klinkum Erlangen, Erlangen, Germany

[15] Univ Hosp Halle, Halle, Saale, Germany

[16] Schwarzwald Baar Klinikum, Villingen Schwenningen, Germany

[17] Univ Freiburg, Freiburg, Germany

[18] Otto von Guericke Univ, Magdeburg, Germany

[19] Schon Klin Starnberger See, Berg, Germany

来源：

LEUKEMIA | 2017年 / 31卷 / 06期

关键词：

STEM-CELL TRANSPLANTATION; INDUCTION; THERAPY; PHASE-3;

D O I：

10.1038/leu.2017.83

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：1463 / 1466

页数：5

共 50 条

[31] Impact of maintenance therapy on subsequent treatment in patients with newly diagnosed multiple myeioma: use of "progression-free survival 2" as a clinical trial end-point
Dimopoulos, Meletios A.
Petrucci, Maria T.
Foa, Robin
Catalano, John
Kropff, Martin
Terpos, Evangelos
Zhang, Jingshan
Grote, Lara
Jacques, Christian
Palumbo, Antonio
HAEMATOLOGICA, 2015, 100 (08) : E328 - E330
[32] Six-month progression-free survival as an alternative primary efficacy endpoint to overall survival in newly diagnosed glioblastoma patients receiving temozolomide
Polley, Mei-Yin C.
Lamborn, Kathleen R.
Chang, Susan M.
Butowski, Nicholas
Clarke, Jennifer L.
Prados, Michael
NEURO-ONCOLOGY, 2010, 12 (03) : 274 - 282
[33] Tolerance, Kinetics, and Depth of Response for Subcutaneous Versus Intravenous Administration of Bortezomib Combination in Chinese Patients With Newly Diagnosed Multiple Myeloma
Xu, Yan
Deng, Shuhui
Mao, Xuehan
An, Gang
Li, Zengjun
Wang, Yafei
Fulciniti, Mariateresa
Ho, Matthew
Lin, Jianhong
Sui, Weiwei
Liu, Wei
Zou, Dehui
Yi, Shuhua
Huang, Wenyang
Liu, Hong
Lv, Rui
Li, Jian
Wang, Tingyu
Du, Chenxing
Munshi, Nikhil C.
Qiu, Lugui
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2018, 18 (06) : 422 - 430
[34] Ixazomib, lenalidomide and dexamethasone consolidation with randomized ixazomib or lenalidomide maintenance after autologous transplant in newly diagnosed multiple myeloma
Slade, Michael
Martin, Thomas G.
Nathwani, Nitya
Fiala, Mark A.
Rettig, Michael P.
Gao, Feng
Deol, Abhinav
Buadi, Francis K.
Kaufman, Jonathan L.
Hofmeister, Craig C.
Gregory, Tara K.
Berdeja, Jesus
Chari, Ajai
Rosko, Ashley
Vij, Ravi
LEUKEMIA, 2022, 36 (12) : 2917 - 2921
[35] Association of Minimal Residual Disease Negativity Rates With Progression Free Survival in Frontline Therapy Trials for Newly Diagnosed Multiple Myeloma: A Meta-analysis
Ficek, Joseph
Kalaitzaki, Eleftheria
Yuan, Shuai Sammy
Tosolini, Alessandra
Du, Ling
Kremer, Brandon E.
Davy, Katherine
Zhou, Helen
Chen, Tai-Tsang
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 (05) : E213 - E221
[36] A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients
Sher, Taimur
Ailawadhi, Sikander
Miller, Kena C.
Manfredi, Debbie
Wood, Margaret
Tan, Wei
Wilding, Gregory
Czuczman, Myron S.
Hernandez-Ilizaliturri, Francisco J.
Hong, Fredrick
Sood, Raman
Soniwala, Saif
Lawrence, William
Jamshed, Saad
Masood, Aisha
Iancu, Daniel
Lee, Kelvin
Chanan-Khan, Asher
BRITISH JOURNAL OF HAEMATOLOGY, 2011, 154 (01) : 104 - 110
[37] Combining bortezomib to high dose melphalan as conditioning regimen results in the improvement of the response rate in newly diagnosed young multiple myeloma patients
Dalla Palma, Benedetta
Accardi, Fabrizio
Prezioso, Lucia
Notarfranchi, Laura
Giuliani, Nicola
LEUKEMIA & LYMPHOMA, 2020, 61 (05) : 1238 - 1241
[38] Serum levels of soluble programmed death ligand 1 predict treatment response and progression free survival in multiple myeloma
Wang, Liang
Wang, Hua
Chen, Hao
Wang, Wei-da
Chen, Xiao-qin
Geng, Qi-rong
Xia, Zhong-jun
Lu, Yue
ONCOTARGET, 2015, 6 (38) : 41228 - 41236
[39] A patient survey indicates quality of life and progression-free survival as equally important outcome measures in multiple myeloma clinical trials
Fleischer, Anna
Zapf, Larissa
Allgaier, Johannes
Jordan, Karin
Gelbrich, Goetz
Pryss, Ruediger
Schobel, Johannes
Bittrich, Max
Einsele, Hermann
Kortuem, Martin
Maatouk, Imad
Weinhold, Niels
Rasche, Leo
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2023, 149 (14) : 12897 - 12902
[40] Thalidomide consolidation improves progression-free survival in myeloma with normal but not up-regulated expression of fibroblast growth factor receptor 3: analysis from the Australasian Leukaemia and Lymphoma Group MM6 clinical trial
Ho, P. Joy
Brown, Ross D.
Spencer, Andrew
Jeffels, Melinda
Daniher, Daniel
Gibson, John
Joshua, Douglas E.
LEUKEMIA & LYMPHOMA, 2012, 53 (09) : 1728 - 1734

← 1 2 3 4 5 →